Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer

Programmed death‐ligand 1 (PD‐L1) expression status is inadequate for indicating nivolumab in patients with non–small cell lung cancer (NSCLC). Because the baseline advanced lung cancer inflammation index (ALI) is reportedly associated with patient outcomes, we investigated whether the pretreatment...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Shiroyama, Takayuki, Suzuki, Hidekazu, Tamiya, Motohiro, Tamiya, Akihiro, Tanaka, Ayako, Okamoto, Norio, Nakahama, Kenji, Taniguchi, Yoshihiko, Isa, Shun‐ichi, Inoue, Takako, Imamura, Fumio, Atagi, Shinji, Hirashima, Tomonori
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5773945/
https://ncbi.nlm.nih.gov/pubmed/29150906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1234
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados